ATE253364T1 - Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen - Google Patents
Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungenInfo
- Publication number
- ATE253364T1 ATE253364T1 AT99961750T AT99961750T ATE253364T1 AT E253364 T1 ATE253364 T1 AT E253364T1 AT 99961750 T AT99961750 T AT 99961750T AT 99961750 T AT99961750 T AT 99961750T AT E253364 T1 ATE253364 T1 AT E253364T1
- Authority
- AT
- Austria
- Prior art keywords
- olanzapine
- disorder
- oxide
- treatment
- oxides
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- LJVNYCDXBXGQIK-UHFFFAOYSA-N chembl440512 Chemical compound S1C(C)=CC2=C1NC1=CC=CC=C1N=C2N1CC[N+](C)([O-])CC1 LJVNYCDXBXGQIK-UHFFFAOYSA-N 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 2
- 229960005017 olanzapine Drugs 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010017543 Fungal skin infection Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000003001 depressive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008406 drug-drug interaction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000016686 tic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10955198P | 1998-11-23 | 1998-11-23 | |
| PCT/US1999/027644 WO2000030649A1 (en) | 1998-11-23 | 1999-11-22 | Pharmaceutical compositions containing olanzapine-n-oxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE253364T1 true ATE253364T1 (de) | 2003-11-15 |
Family
ID=22328264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99961750T ATE253364T1 (de) | 1998-11-23 | 1999-11-22 | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6121259A (de) |
| EP (1) | EP1135136B1 (de) |
| JP (1) | JP2002530340A (de) |
| AT (1) | ATE253364T1 (de) |
| AU (1) | AU757870B2 (de) |
| CA (1) | CA2351719A1 (de) |
| DE (1) | DE69912635T2 (de) |
| ES (1) | ES2211205T3 (de) |
| WO (1) | WO2000030649A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| CA2364211A1 (en) * | 2000-12-05 | 2002-06-05 | Phillip Branch Chappell | Combination treatment for depression, anxiety and psychosis |
| TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
| EP1551393A4 (de) * | 2002-07-30 | 2010-06-16 | Peter Migaly | Kombinationstherapie gegen depression, prävention von suizid und verschiedener medizinischer und psychiatrischer erkrankungen |
| NZ556779A (en) | 2002-12-27 | 2008-12-24 | Otsuka Pharma Co Ltd | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| WO2007137224A2 (en) * | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Method of treatment |
| US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
| CN101711236B (zh) * | 2007-04-12 | 2012-10-31 | Nsab神经研究瑞典公司分公司 | 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 |
| US9018202B2 (en) | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4115568A (en) * | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5627178A (en) * | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| US6274636B1 (en) * | 1995-09-29 | 2001-08-14 | Eli Lilly And Company | Method for treating a tic disorder |
| JP2000502346A (ja) * | 1995-12-21 | 2000-02-29 | イーライ・リリー・アンド・カンパニー | 皮膚炎の処置方法 |
| CZ198498A3 (cs) * | 1995-12-22 | 1999-03-17 | Eli Lilly And Company | Použití 2-methyl-4-(4-methyl)-piperazinyl)-10H-thieno[2,3b][1,5]benzodiazepinu |
| UA57727C2 (uk) * | 1996-03-11 | 2003-07-15 | Елі Ліллі Енд Компані | Спосіб лікування надмірної агресивності |
| WO1997033585A1 (en) * | 1996-03-11 | 1997-09-18 | Eli Lilly And Company | Method for treating autism |
| TR199801801T2 (xx) * | 1996-03-11 | 1998-12-21 | Eli Lilly And Company | Madde k�t�ye kullan�m�n�n tedavisi. |
| CN1213966A (zh) * | 1996-03-11 | 1999-04-14 | 伊莱利利公司 | 治疗两极紊乱的方法 |
| GB9615767D0 (en) * | 1996-07-26 | 1996-09-04 | Smithkline Beecham Plc | Novel treatment |
-
1999
- 1999-11-22 DE DE69912635T patent/DE69912635T2/de not_active Expired - Fee Related
- 1999-11-22 US US09/444,159 patent/US6121259A/en not_active Expired - Fee Related
- 1999-11-22 EP EP99961750A patent/EP1135136B1/de not_active Expired - Lifetime
- 1999-11-22 AU AU18266/00A patent/AU757870B2/en not_active Ceased
- 1999-11-22 ES ES99961750T patent/ES2211205T3/es not_active Expired - Lifetime
- 1999-11-22 WO PCT/US1999/027644 patent/WO2000030649A1/en not_active Ceased
- 1999-11-22 CA CA002351719A patent/CA2351719A1/en not_active Abandoned
- 1999-11-22 JP JP2000583532A patent/JP2002530340A/ja active Pending
- 1999-11-22 AT AT99961750T patent/ATE253364T1/de not_active IP Right Cessation
-
2000
- 2000-08-07 US US09/632,584 patent/US6352984B1/en not_active Expired - Fee Related
-
2001
- 2001-10-30 US US10/016,205 patent/US20020065272A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000030649A1 (en) | 2000-06-02 |
| US6121259A (en) | 2000-09-19 |
| JP2002530340A (ja) | 2002-09-17 |
| US6352984B1 (en) | 2002-03-05 |
| EP1135136B1 (de) | 2003-11-05 |
| DE69912635T2 (de) | 2004-05-13 |
| AU1826600A (en) | 2000-06-13 |
| DE69912635D1 (de) | 2003-12-11 |
| US20020065272A1 (en) | 2002-05-30 |
| CA2351719A1 (en) | 2000-06-02 |
| AU757870B2 (en) | 2003-03-06 |
| EP1135136A1 (de) | 2001-09-26 |
| ES2211205T3 (es) | 2004-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69912635D1 (de) | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen | |
| ATE286398T1 (de) | Desmethylolanzapine enthaltende zusammensetzungen und verfahren | |
| BRPI0413022A (pt) | derivados de 3-amino cromado e 2-amino tetralina | |
| PT751939E (pt) | Naftilamidas como agentes para o sistema nervoso central | |
| DE60040487D1 (de) | Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität | |
| BRPI0402420A (pt) | Processos de toner | |
| BR9913585A (pt) | Formulação de toxina botulinum farmacêutica lìquida estável, método de tratar um paciente em necessidade de inibição de entrada colinérgica em um músculo selecionado, grupo de músculos, glândula ou órgão, e, uso de uma formulação de toxina botulinum lìquida estável | |
| PT839143E (pt) | Compostos de tetralina com actividade mdr | |
| ATE302269T1 (de) | Ste20-verwandte proteinkinasen | |
| DE60027077D1 (de) | Reinigungszusammensetzung zur Behandlung und/oder Verbesserung von Schuppen, Dermatitis seborrhoeica, Psoriasis und Ekzemen und deren Symptomen | |
| DE60103927D1 (de) | Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems | |
| ATE233318T1 (de) | Spezifische oligonukleotide für hepatitis b virus | |
| ES2168457T3 (es) | Composiciones farmaceuticas que comprenden una superoxido dismutasa. | |
| DE60231507D1 (de) | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten | |
| Jia et al. | Exploring the adverse effects of the metaverse on users’ psychological well-being and Self-Esteem: A mixed-methods study | |
| BR9801643A (pt) | Compostos precursores de fragâncias. | |
| PT1047449E (pt) | Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal | |
| BR9910958A (pt) | Composição para cuidar de cabelo, e, processo para condicionar e conferir corpo ao cabelo | |
| JP2002530341A5 (de) | ||
| DE69808119D1 (de) | Diskontinuierliches und kontinuierliches gegenstromstoffaustauschverfahren | |
| Daube et al. | Translesion replication by DNA polymerase β is modulated by sequence context and stimulated by fork-like flap structures in DNA | |
| DE69810524D1 (de) | Polyethylenterephthalatharzzusammensetzung, geformtes Produkt und Modifikationsverfahren | |
| DE69927416D1 (de) | Globale regulatoren von pathogenen bakteriellen genen; bakterielles selbstinduzierendes inaktivierungsprotein, die als ziele für die herstellung von krankheitsresistenzen einsetzbar sind | |
| Mora | Mesillaros and Gringo Mexicans: The changing meanings of race, nation, and space in Southern New Mexico, 1848–1912 | |
| PT1326616E (pt) | Utilizacao de quetiapina para o disturbio de defice de atencao com hiperactividade ou disturbio de conduta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |